Chemotherapy-based treatment for castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3686-3694

  Seruga, Bostjan ^a   Tannock, Ian F ^b  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ALPHARADIN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CUSTIRSEN; DASATINIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; IXABEPILONE; KETOCONAZOLE; LENALIDOMIDE; MITOXANTRONE; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ZIBOTENTAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG COST; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; HUMAN; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 80053062749     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3996     Document Type: Review

References (70)

1. Eisenberger MA, Walsh PC: Early androgen deprivation for prostate cancer? N Engl J Med 341:1837-1838, 1999
2. Ryan CJ, Small EJ: Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 62:87-94, 2003 (suppl 1)
3. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985 (Pubitemid 15062911)
4. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
5. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993 (Pubitemid 23049638)
6. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996 (Pubitemid 26185452)
7. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506-2513, 1999 (Pubitemid 29368252)
8. Tannock IF, De Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
9. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
10. Small E, Demkow T, Gerritsen WR, et al: A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Proceedings Genitourinary Cancer Symposium, Orlando, FL, February 26-28, 2009 (suppl; abstr 7)
11. Scher HI, Jia X, Chi K, et al: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29:2191-2198, 2011
12. Kelly WK, Halabi S, Carducci MA, et al: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28:344s, 2010 (suppl; abstr LBA4511)
13. Sternberg CN, Petrylak DP, Sartor O, et al: Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 27:5431-5438, 2009
14. De Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
15. De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
16. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
17. Shepard DR, Weil A, Garcia JA, et al: Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. J Clin Oncol 28:388s, 2010 (suppl; abstr 4687)
18. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006 (Pubitemid 43898814)
19. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965-3970, 2007 (Pubitemid 47477275)
20. Armstrong AJ, Tannock IF, De Wit R, et al: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517-525, 2010
21. Armstrong AJ, Garrett-Mayer E, De Wit R, et al: Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203-211, 2010
22. Reid AH, Attard G, Ambroisine L, et al: Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678-684, 2010
23. Tomlins SA, Mehra R, Rhodes DR, et al: Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41-51, 2007 (Pubitemid 46026500)
24. Berges RR, Vukanovic J, Epstein JI, et al: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995
25. Pinski J, Parikh A, Bova GS, et al: Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 61:6372-6376, 2001 (Pubitemid 32783240)
26. Shah RB, Mehra R, Chinnaiyan AM, et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 64:9209-9216, 2004 (Pubitemid 39665537)
27. Pienta KJ, Smith DC: Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 55:300-318, 2005 (Pubitemid 41377334)
28. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194-204, 2010
29. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997 (Pubitemid 27038278)
30. Zhu ML, Horbinski CM, Garzotto M, et al: Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992-8002, 2010
31. Seruga B, Ocana A, Tannock IF: Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12-23, 2011
32. Scher HI, Beer TM, Higano CS, et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 375:1437-1446, 2010
33. Siegsmund MJ, Kreukler C, Steidler A, et al: Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 25:35-41, 1997 (Pubitemid 27141802)
34. Theyer G, Schirmböck M, Thalhammer T, et al: Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 150:1544-1547, 1993 (Pubitemid 24356225)
35. Terry S, Ploussard G, Allory Y, et al: Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 101:951-956, 2009
36. Ploussard G, Terry S, Maillé P, et al: Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxelbased chemotherapy. Cancer Res 70:9253-9264, 2010
37. Raffo AJ, Perlman H, Chen MW, et al: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445, 1995
38. Zhang M, Latham DE, Delaney MA, et al: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24:2474-2482, 2005 (Pubitemid 40593038)
39. Yang CC, Lin HP, Chen CS, et al: Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 278:25872-25878, 2003
40. Zoubeidi A, Chi K, Gleave M: Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16:1088-1093, 2010
41. Trédan O, Galmarini CM, Patel K, et al: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441-1454, 2007
42. Kyle AH, Huxham LA, Yeoman DM, et al: Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res 13:2804-2810, 2007 (Pubitemid 46788050)
43. Heldin CH, Rubin K, Pietras K, et al: High interstitial fluid pressure: An obstacle in cancer therapy. Nat Rev Cancer 4:806-813, 2004 (Pubitemid 39331152)
44. Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447, 2004 (Pubitemid 38745529)
45. Franke RM, Carducci MA, Rudek MA, et al: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567, 2010
46. Beer TM, Myrthue A: Calcitriol in the treatment of prostate cancer. Anticancer Res 26:2647-2651, 2006
47. Beer TM, Ryan CW, Venner PM, et al: Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 25:669-674, 2007 (Pubitemid 350002922)
48. Mucci LA, Powolny A, Giovannucci E, et al: Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627-5633, 2009
49. George DJ, Halabi S, Shepard TF, et al: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932-1936, 2001 (Pubitemid 32994827)
50. Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res 61:2533-2536, 2001 (Pubitemid 32685834)
51. Picus J, Halabi S, Kelly WK, et al: A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: Results from Cancer and Leukemia Group B Study 90006. Cancer 117:526-533, 2011
52. Ocaña A, Amir E, Vera F, et al: Addition of bevacizumab to chemotherapy for treatment of solid tumors: Similar results but different conclusions. J Clin Oncol 29:254-256, 2011
53. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008
54. Pfizer: Pfizer Discontinues Phase 3 Trial of SUTENT in Advanced Castration-Resistant Prostate Cancer. http://pfizer.mediaroom.com/index.php?s= 5149&item=14036
55. Ning YM, Gulley JL, Arlen PM, et al: Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:2070-2076, 2010
56. Oh WK, Tay MH, Huang J: Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 109:477-486, 2007 (Pubitemid 46190955)
57. Attard G, Greystoke A, Kaye S, et al: Update on tubulin-binding agents. Pathol Biol (Paris) 54:72-84, 2006
58. Pivot X, Koralewski P, Hidalgo JL, et al: A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547-1552, 2008
59. ClinicalTrials.gov: Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment. http://clinicaltrials. gov/show/NCT01140607
60. Shih YC, Halpern MT: Economic evaluations of medical care interventions for cancer patients: How, why, and what does it mean? CA Cancer J Clin 58:231-244, 2008
61. Mita AC, Denis LJ, Rowinsky EK, et al: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723-730, 2009
62. Lee JJ, Kelly WK: Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 6:85-92, 2009
63. Fojo AT, Menefee M: Microtubule targeting agents: Basic mechanisms of multidrug resistance (MDR). Semin Oncol 32:S3-S8, 2005 (Pubitemid 41785440)
64. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001 (Pubitemid 32708699)
65. Orr GA, Verdier-Pinard P, McDaid H, et al: Mechanisms of Taxol resistance related to microtubules. Oncogene 22:7280-7295, 2003 (Pubitemid 37487160)
66. Rosenberg JE, Weinberg VK, Kelly WK, et al: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556-563, 2007 (Pubitemid 47106144)
67. Beardsley EK, Saad F, Eigl B, et al: A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 27:268s, 2009 (suppl; abstr 5139)
68. Chi KN, Hotte SJ, Yu EY, et al: Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254, 2010
69. Loriot Y, Massard C, Gross-Goupil M, et al: The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46:1770-1772, 2010
70. Eymard JC, Oudard S, Gravis G, et al: Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: A retrospective multicentre study. BJU Int 106:974-978, 2010